Nimusilide use
Reading File
Finding Sources
Searching PubMed
nimesulide clinical use safety
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
Here is a comprehensive overview of Nimesulide based on authoritative medical textbooks:
Nimesulide - Clinical Overview
Drug Class & Mechanism
Nimesulide is a non-steroidal anti-inflammatory drug (NSAID) with preferential COX-2 selectivity. Although it was not purpose-designed as a COX-2 inhibitor, it was retrospectively found to have COX-2 selectivity comparable to celecoxib. It sits at the intermediate level of COX-2 selectivity - similar to diclofenac and celecoxib - meaning it has a reasonable probability of sparing COX-1 at therapeutic plasma concentrations. It does not reach the high-grade COX-2 selectivity of rofecoxib or etoricoxib. - Rheumatology, 2-Volume Set (Elsevier, 2022)
Other mechanisms beyond COX inhibition include inhibition of platelet-activating factor, phosphodiesterase type IV, histamine release, and superoxide generation - contributing to its anti-inflammatory profile through multiple pathways.
Indications
| Indication | Details |
|---|---|
| Pain & inflammation | Acute and chronic pain, osteoarthritis, musculoskeletal disorders |
| Dysmenorrhea | Superior to placebo; listed alongside ibuprofen, naproxen, ketoprofen, and mefenamic acid as effective NSAIDs. Treatment should begin before onset of menses and continue 2-3 days - Harrison's Principles of Internal Medicine, 22E (2025) |
| Fever | Antipyretic use, especially in adults |
| Tocolysis (limited) | Has been compared with indomethacin and sulindac in preterm labor management, though not a first-line agent - Creasy & Resnik's Maternal-Fetal Medicine |
Pharmacokinetics
- Oral bioavailability: Well absorbed orally
- Protein binding: High (>95%), typical of NSAIDs
- Half-life: Approximately 1.5-5 hours
- Metabolism: Hepatic (via CYP enzymes)
- Standard adult dose: 100 mg twice daily (max 200 mg/day); treatment duration typically limited to 15 days
Regulatory Status
Nimesulide has a very heterogeneous global regulatory status:
| Region | Status |
|---|---|
| United States | Not marketed / not approved |
| India, Italy, parts of Europe/Asia | Available (with restrictions) |
| Ireland, Finland, Spain | Withdrawn due to hepatotoxicity concerns |
| EU overall | Marketed in some countries; withdrawn in others - Rheumatology, 2-Volume Set (2022) |
Adverse Effects
Hepatotoxicity (Major Concern)
This is the most significant safety issue with nimesulide:
- Linked to acute hepatitis and fatal hepatic failure, especially in women - Sleisenger & Fordtran's GI and Liver Disease
- Onset: typically 1 to 15 weeks after starting the drug (occasionally up to 8 months)
- Risk factors: treatment duration >30 days, higher doses, concomitant hepatotoxic drugs
- Hypersensitivity features with peripheral eosinophilia may occur
- Liver histology: centrilobular or bridging necrosis; occasionally bland cholestasis
- Resolution after stopping drug: 2 to 17 months
- Observational studies place nimesulide among the NSAIDs with the highest risk of liver injury (alongside sulindac and diclofenac) - Rheumatology, 2-Volume Set (2022)
GI Effects
- Relatively better GI tolerability than non-selective NSAIDs due to COX-2 preference, but GI risk is not eliminated
Renal / Fetal Effects
- As a COX inhibitor, it reduces fetal urine production and can cause oligohydramnios and ductal constriction in utero - comparable to indomethacin and sulindac - Creasy & Resnik's Maternal-Fetal Medicine
Cardiovascular
- Like all NSAIDs with intermediate-high COX-2 selectivity, some cardiovascular risk applies, particularly with long-term use
Contraindications & Precautions
- Avoid in hepatic impairment (significant hepatotoxicity risk)
- Avoid in pregnancy (especially after 32 weeks - ductal constriction, oligohydramnios)
- Avoid with other hepatotoxic drugs
- Not for use > 15 days (recommended maximum treatment duration in most markets)
- Not for children (banned in pediatric use in most countries due to Reye's-like hepatotoxicity reports)
- Avoid in known sulfonamide allergy (cross-reactivity possible, as with some NSAIDs)
Key Takeaway
Nimesulide occupies a niche as a moderately COX-2 selective NSAID with good analgesic and anti-inflammatory efficacy, used mainly in countries where it is still approved (notably India). Its use is restricted by hepatotoxicity concerns - the most distinguishing feature in its safety profile - which led to withdrawal in several Western countries. When used, it should be at the lowest effective dose for the shortest duration (max 15 days) with monitoring of liver function.
Can be givem for migrane?
Finding Sources
Finding Sources
Reading File
Reading File
Yes - nimesulide can be used for migraine, but with important caveats. Here is what the evidence and textbooks say:
Nimesulide in Migraine
Can it be used? Yes - as an NSAID for mild-to-moderate migraine
NSAIDs as a class are well-established for migraine treatment. As Harrison's (22nd Ed, 2025) states:
"Both the severity and duration of a migraine attack can be reduced significantly by NSAIDs... NSAIDs are most effective when taken early in the migraine attack. However, the effectiveness of these agents is usually less than optimal in moderate or severe migraine attacks."
Since nimesulide is a COX-2 preferential NSAID with analgesic and anti-inflammatory properties, it can reduce migraine pain, especially for mild attacks when taken at the very start of symptoms.
Where nimesulide fits in the migraine treatment hierarchy
| Migraine Severity | Preferred Treatment | Role of Nimesulide |
|---|---|---|
| Mild | OTC NSAIDs (ibuprofen, aspirin, naproxen), paracetamol | Can be used as an alternative NSAID |
| Moderate | Triptans, NSAIDs, combination therapy | Second-line; triptans preferred |
| Severe | Triptans, dihydroergotamine, gepants (rimegepant, ubrogepant) | Not indicated |
| Very severe / ED | IV prochlorperazine, metoclopramide, ketorolac | Not used |
Specifically named NSAIDs in guidelines include aspirin (250-1000 mg), ibuprofen (400-600 mg), naproxen (500-825 mg), diclofenac (50 mg), and ketoprofen (75 mg) - Goldman-Cecil Medicine. Nimesulide is not specifically named in these standard lists, as it is unavailable in the US/UK where most guidelines originate.
Practical considerations
- Nimesulide 100 mg orally at onset can reduce migraine pain via prostaglandin inhibition
- It may be slightly better tolerated GI-wise than non-selective NSAIDs like aspirin or ibuprofen for patients prone to GI upset with migraine
- Not for frequent/repeated use - the 15-day maximum treatment duration applies, and medication overuse headache (MOH) is a risk with any analgesic used more than 10-15 days/month
- In countries where nimesulide is available (like India), it is sometimes used clinically for mild-moderate migraine attacks as a practical NSAID option
- Not a migraine-specific drug - it has no action on serotonin receptors (5-HT1B/1D), CGRP, or dopamine receptors like triptans, gepants, or ditans
Bottom Line
Nimesulide can be given for mild-to-moderate migraine, particularly at onset, as part of the NSAID class approach. However, it is not a first-line or specifically recommended migraine drug in any major guideline. For moderate-to-severe attacks, triptans remain the preferred choice. Avoid frequent use to prevent medication overuse headache.
This is a shared conversation. Sign in to Orris to start your own chat.